Background: Chordoma, a rare tumor arising from notochordal remnants, has b
een described to date only by single-institution case series or small popul
ation-based surveys.
Methods: We used data from the Surveillance, Epidemiology, and End Results
(SEER) program of the National Cancer Institute, 1973-1995, to calculate ag
e-adjusted incidence and survival rates for 400 cases of microscopically co
nfirmed chordoma and to derive information regarding case distribution and
risk of second cancer.
Results: The age-adjusted chordoma incidence rate (IR) of 0.08 per 100,000
was age-dependent, more common in males (IR 0.10) than females (IR 0.06) an
d rare among patients aged < 40 years and blacks. Within the axial skeleton
32% of cases were cranial, 32.8% spinal and 29.2% sacral. Young age (< 26
years; p = 0.0001) and female sex (p = 0.037) were associated with greater
likelihood of cranial presentation. There was no overall increased risk for
second primary cancers after chordoma. Median survival was 6.29 years; 5-
and 10-year relative survival rates were 67.6% and 39.9%, respectively. Com
parison with other bone sarcomas revealed racial disparities in incidence f
or the two developmental tumors, chordoma and Ewing's sarcoma.
Conclusions: This study provides new data regarding incidence and survival
patterns of chordoma in the US. Additional epidemiologic studies are requir
ed to elucidate the genetic and environmental determinants underlying this
rare, distinctive neoplasm.